Previous close | 246.53 |
Open | 246.50 |
Bid | 251.41 x 800 |
Ask | 259.82 x 800 |
Day's range | 244.32 - 252.16 |
52-week range | 229.40 - 277.29 |
Volume | |
Avg. volume | 1,152,824 |
Market cap | 71.779B |
Beta (5Y monthly) | 0.66 |
PE ratio (TTM) | 39.65 |
EPS (TTM) | 6.35 |
Earnings date | 03 Aug 2022 - 08 Aug 2022 |
Forward dividend & yield | 3.48 (1.38%) |
Ex-dividend date | 08 Jun 2022 |
1y target est | 280.91 |
BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.
BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.
BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.